Experimental infections of mice with the African trypanosome Trypanosoma brucei lead to a profound state of T-cell unresponsiveness in the lymph node cell (LNC) compartment (18) . This suppression was found to be mediated by macrophage-like cells which inhibit interleukin-2 (IL-2) production via prostaglandin secretion and inhibit IL-2 receptor (IL-2R) expression via a prostaglandin-independent mechanism (17) . The simultaneous suppression of IL-2 production and IL-2R expression does not reflect a total unresponsiveness of mitogen-activated T cells. Indeed, we have reported that LNC from T. brucei-infected mice (LNCi) were perfectly able to secrete lymphokines other than IL-2, such as gamma interferon (IFN--y) (19) . Other investigators have demonstrated that infections of rats with T. brucei induce a strong and rapid increase in the number of IFN-y-producing cells of the CD8+ phenotype (1) . Thus, it appears that infections with T. brucei exert dual activities on the T-cell response: profound inhibition of T-cell proliferation and sensibilization for IFN--y production. In view of the multiple immunosuppressive activities of IFN-,y (3, 11, 12) , it was of interest to analyze whether IFN--y is involved, as a mediator, in the T. brucei-elicited impairment of T-cell proliferation.
The pleomorphic T. brucei AnTat l.l.E clone, kindly provided by N. Van Meirvenne (Institute of Tropical Medicine, Antwerp, Belgium), was used in all the experiments. brucei-infected mice reaches its peak at week 3 after infection (19) . Therefore, in all the experiments the LNC from infected mice were isolated at week 4 (21) and the rat anti-mouse IFN--y MAb Fl (9) . All experiments described here were repeated at least twice and found to be consistently reproducible.
For in vivo and in vitro neutralization of endogenous murine IFN-,y, the neutralizing rat MAb F3 was used. The potential of this antibody to bind IFN-y and to neutralize antiviral effects has been described elsewhere (9) . The antibody was obtained as ascitic fluid from thymusless nude mice (nu/nu). The neutralizing batch used in the present study was Supernatants of ConA-activated LNC, LNCi, and cocultures of LNCi with LNC were tested for their capacity to prime the bioluminescent activity of a macrophage hybridoma cell line. This macrophage activation assay proved to be reliable for the detection and quantification of MAF such as IFN--y (2). As shown in Fig. 1A , LNCi as well as cocultures of LNCi with LNC produced an increased and accelerated MAF response compared with that of LNC. In characterization experiments, this MAF activity was found to be completely blocked by neutralizing anti-IFN--y antibodies. Furthermore, by means of an IFN--y-specific ELISA, enhanced IFN-y production was detected in the supematant of LNCi and cocultures of LNC and LNCi (Fig. 1B) trol and anti-IFN--y-treated groups, and no differences in the survival rates of the different experimental groups were observed. These observations indicate that the IFN-.y-mediated immunosuppression in the LNC compartment is not directly related to the control of T. brucei infections. This does not completely exclude a possible connection between a state of immunosuppression and parasite development since the splenic compartment remained suppressed during anti-IFN--y treatment (Table 2) . According to the results described here, IFN-y appears to act as a key molecule in T. brucei-elicited suppression of T-cell proliferative responses, at least as far as the LNC compartment is concerned. T. brucei-mediated induction of IFN--y production may represent the first event in the pathway of suppression. According to another report (1) , very large numbers of IFN--y-producing CD8+ T cells can be detected in T. brucei-infected rats as early as 12 h postinfection. This fast IFN-y production in vivo is most probably induced directly by the parasite, since T. brucei-released factors were described as capable of triggering in a nonantigen-specific way a rapid release of IFN-y by CD8+ cells a LNC cultured at a concentration of 4 x 106/ml were stimulated with ConA. Cocultures of LNC (2 x 106/ml) and LNCi (2 x 106/ml) were made to evaluate the suppressive activity of LNCi on the response of LNC. LNCi were harvested from T. brucei-infected animals that were either untreated or treated with anti-IFN-y (treatment 6 h before [-6 h] (14) . Local hyperproduction of IFN--y may in turn affect immune responsiveness through macrophage activation, for instance. In fact, experimental infections with T. brucei result in the activation of macrophages, as evidenced by an increase in class II major histocompatibility complex expression (8) , enhanced release of reactive oxygen components (5) and prostaglandins, and increased production of IL-1 (16 (10) . IFN--y-treated macrophages were found to be inhibited in their capacity to induce antigen-specific T-cell proliferation, and the underlying mechanism of inhibition was unrelated to class II major histocompatibility complex expression, IL-1 secretion, and prostaglandin secretion (12) .
Besides playing a potential role in the generation of suppressive macrophages, IFN--y seems to be also involved directly in the inhibition of IL-2R expression and T-cell proliferation. Indeed, addition of anti-IFN-y to cocultures of LNCi and LNC restored both the proliferative response and the expression of IL-2R. Antiproliferative activities of IFN-y were reported for Th2 cells (4, 6) , B cells (13) , and bone marrow cells (7). In the experiments described above, however, the inhibition of T-cell proliferation is probably not due to an action of IFN-y alone, since supplying 1,000 U of exogenous IFN-y to ConA-activated LNC did not influence the mitogenic response (data not shown). Hence, the inhibitory activity of IFN--y on IL-2R expression and T-cell proliferation requires other, ill-defined cofactors. The availability of an in vitro model that enables mimicry of the suppressive activity of T. brucei-elicited macrophage suppressor cells (15) will be useful in the identification of these putative suppressive cofactors.
In summary, on the basis of our accumulated data on T. brucei-elicited suppression in the LNC compartment, at least two soluble mediators appear to be involved in the pathway of suppression: (i) prostaglandins inhibiting IL-2 secretion (18) and (ii) IFN--y which is involved in both the generation of suppressive cells and the prostaglandin-independent suppression of IL-2R expression. It is worth stressing that the IFN--y-dependent pathway of suppression seems to occur only in the lymph node and not in the splenic compartment. Indeed, while anti-IFN--y treatment restored the impaired proliferative effect of LNC, no restoration was observed in SPC populations. Recently, Stemnberg and McGuigan (20) reported that nitric oxide (NO) released by macrophages mediates suppression of splenic T-cell responses in murine T. brucei infections. In these studies, suppression could be abrogated by NG-monomethyl-L-arginine (L-NMMA), a competitive inhibitor of arginine-dependent NO synthetase. We have tested the influence of L-NMMA on cocultures of LNCi and LNC and found no influence of this NO inhibitor on the suppressed response of LNC (data not shown). Hence, murine T. brucei infections may elicit two distinct suppressive mechanisms in different lymphoid compartments: an IFN--y-dependent mechanism in lymph nodes and an NO-dependent mechanism in the spleen.
